Evelo Biosciences, Inc.
Evelo Biosciences, Inc. (EVLO) Stock Overview
Explore Evelo Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Company Profile
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Mr. Craig R. Jalbert CIRA
66
620 Memorial Drive, Cambridge, MA
2018